Drug Profile
Research programme: obesity therapeutics - Metagenics
Latest Information Update: 27 Nov 2017
Price :
$50
*
At a glance
- Originator Metagenics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 27 Nov 2017 Interleukin Genetics has been acquired and merged into ORIG3N
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 24 May 2012 Preclinical trials in Obesity in USA (unspecified route)